Boostrix-IPV combination vaccine

ApprovedVaccine

UUniversity of Oxford

Boostrix-IPV combination vaccine is one of 3 biologic programs targeting Whooping Cough. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Whooping CoughActive, not recruiting

Whooping CoughApproved

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Whooping Cough

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—2

E-Mycin

AAzurity Pharmaceuticals

Approved

—3

Boostrix-IPV combination vaccine

UUniversity of Oxford

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Whooping Cough1 trial

A Study Exploring Whooping Cough Protection in Children and Adults

Completed·UUniversity of Oxford·Phase 4·NCT03697798·122 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Boostrix-IPV combination vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Boostrix-IPV combination vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Boostrix-IPV combination vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Oxford company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: UUniversity of Oxford

Boostrix-IPV combination vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Whooping Cough1 trial

References

Drug Info

Quick Facts

Related News